Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Assets (2017 - 2025)

Historic Current Assets for Fennec Pharmaceuticals (FENC) over the last 9 years, with Q3 2025 value amounting to $46.1 million.

  • Fennec Pharmaceuticals' Current Assets fell 2053.14% to $46.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.1 million, marking a year-over-year decrease of 2053.14%. This contributed to the annual value of $44.1 million for FY2024, which is 6428.62% up from last year.
  • Fennec Pharmaceuticals' Current Assets amounted to $46.1 million in Q3 2025, which was down 2053.14% from $40.8 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Current Assets peaked at $68.2 million during Q1 2024, and registered a low of $15.6 million during Q2 2022.
  • In the last 5 years, Fennec Pharmaceuticals' Current Assets had a median value of $27.9 million in 2021 and averaged $34.6 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Current Assets crashed by 4459.64% in 2022, and later surged by 22161.81% in 2024.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Current Assets stood at $26.0 million in 2021, then rose by 2.88% to $26.7 million in 2022, then grew by 0.49% to $26.9 million in 2023, then soared by 64.29% to $44.1 million in 2024, then rose by 4.4% to $46.1 million in 2025.
  • Its Current Assets was $46.1 million in Q3 2025, compared to $40.8 million in Q2 2025 and $43.0 million in Q1 2025.